Kirkwood J, Dummer R, Hauschild A, Santinami M, Atkinson V, Sileni V, Larkin J, Nyakas M, Haydon A, Dutriaux C, Schachter J, Robert C, Mortier L, Banerjee H, Haas T, Tan M, Lau M, Schadendorf D, Long G, Mandala M. Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma. J of Skin [Internet]. 2021 Jan. 1 [cited 2024 Jul. 4];5(1):s2. Available from: https://jofskin.org/33014/index.php/skin/article/view/1154